Tanabe Pharma America, Inc. clinical trials

A country office of Tanabe Pharma Corporation

The registry lists 13 studies whose lead sponsor is Tanabe Pharma America, Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 9, 2026.

Studies

Recruiting first, then most recently updated. Showing 13 of 13. All Tanabe Pharma Corporation studies →

• A Study of MT-4561 in Patients With Various Advanced Solid TumorsRecruitingNCT06943521Phase 1/2

  Sponsor listed in the registry: Tanabe Pharma America, Inc.

• Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Active, not recruitingNCT05005975Phase 3

  Sponsor listed in the registry: Tanabe Pharma America, Inc.

• INcreased Sun Exposure Without Pain In Research Participants With EPP or XLPCompletedNCT06144840Phase 3

  Sponsor listed in the registry: Tanabe Pharma America, Inc.

• MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal WomenCompletedNCT03291067Phase 2

  Sponsor listed in the registry: Tanabe Pharma America, Inc.

• Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor SymptomsCompletedNCT03541200Phase 2

  Sponsor listed in the registry: Tanabe Pharma America, Inc.

• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy SubjectsTerminatedNCT03809039Phase 1

  Sponsor listed in the registry: Tanabe Pharma America, Inc.

• Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic ProtoporphyriaCompletedNCT03520036Phase 2

  Sponsor listed in the registry: Tanabe Pharma America, Inc.

• Safety and Efficacy Study of MT-2990 in Women With EndometriosisCompletedNCT03840993Phase 2

  Sponsor listed in the registry: Tanabe Pharma America, Inc.

• Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic SclerosisCompletedNCT04440592Phase 2

  Sponsor listed in the registry: Tanabe Pharma America, Inc.

• Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked ProtoporphyriaCompletedNCT04402489Phase 3

  Sponsor listed in the registry: Tanabe Pharma America, Inc.

• Definitive QT Study With MT-8554CompletedNCT03471130Phase 1

  Sponsor listed in the registry: Tanabe Pharma America, Inc.

• Mass Balance Study With MT-8554CompletedNCT03381404Phase 1

  Sponsor listed in the registry: Tanabe Pharma America, Inc.

• Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord InjuryCompletedNCT04683848Phase 2

  Sponsor listed in the registry: Tanabe Pharma America, Inc.